Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
Gubareva, L.V., Sleeman, K., Guo, Z., Yang, H., Hodges, E., Davis, C.T., Baranovich, T., Stevens, J.(2017) J Infect Dis 216: S566-S574
- PubMed: 28934455 
- DOI: https://doi.org/10.1093/infdis/jiw625
- Primary Citation of Related Structures:  
5L14, 5L15, 5L17, 5L18 - PubMed Abstract: 
Neuraminidase (NA) inhibitors are the recommended antiviral medications for influenza treatment. However, their therapeutic efficacy can be compromised by NA changes that emerge naturally and/or following antiviral treatment. Knowledge of which molecular changes confer drug resistance of influenza A(H7N9) viruses (group 2NA) remains sparse.
Organizational Affiliation: 
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention.